Trials that use: Log-rank test
New to this method? Read the tutorial →
220 results
- TALAPRO-2Independent statistical analysis of TALAPRO-2, evaluating talazoparib plus enzalutamide versus placebo plus enzalutamide in mCRPC, with detailed interpretation of radiographic progression-free survival and the trial's survival-analysis methods.
- TEAMIndependent statistical analysis of TEAM, the randomized phase 3 trial comparing exemestane with tamoxifen followed by exemestane in postmenopausal patients with receptor-positive breast cancer. Includes disease-free survival, overall survival, time to relapse,…
- TEXTIndependent statistical analysis of TEXT, a randomized phase 3 trial of triptorelin with either exemestane or tamoxifen in premenopausal women with hormone-responsive breast cancer, including time-to-event endpoints, hazard ratios, confidence intervals, log-rank…
- TH3RESAIndependent statistical analysis of TH3RESA, a randomized phase 3 trial of trastuzumab emtansine versus treatment of physician's choice in participants with HER2-positive breast cancer who had received at least two prior HER2-directed…
- THORComplete statistical analysis of the phase 3 THOR trial of erdafitinib in participants with advanced urothelial cancer and selected FGFR gene aberrations, including overall survival, trial design, statistical methodology, and interpretation.
- TITANIndependent statistical analysis of TITAN (NCT02489318), a randomized phase 3 trial of apalutamide plus androgen deprivation therapy versus androgen deprivation therapy in participants with metastatic hormone-sensitive prostate cancer.
- ToGAIndependent statistical analysis of the ToGA phase 3 trial of trastuzumab plus fluoropyrimidine/cisplatin versus fluoropyrimidine/cisplatin alone in patients with HER2-positive advanced gastric cancer, including survival, response, statistical methods, interpretation, and safety.
- TOPAZ-1Independent statistical analysis of TOPAZ-1, evaluating durvalumab plus gemcitabine/cisplatin versus placebo plus gemcitabine/cisplatin in advanced biliary tract cancer, including survival endpoints, response, statistical methods, and interpretation.
- TRITON3Independent statistical analysis of TRITON3, a randomized phase 3 trial of rucaparib versus physician's choice of therapy in metastatic castration-resistant prostate cancer with BRCA or ATM alterations.
- TROPiCS-02Independent statistical analysis of TROPiCS-02, a randomized phase 3 trial of sacituzumab govitecan-hziy versus treatment of physician's choice in participants with HR+/HER2- metastatic breast cancer.
- TROPiCS-04Independent statistical analysis of TROPiCS-04, a randomized phase 3 trial of sacituzumab govitecan versus physician's choice of treatment in locally advanced or metastatic unresectable urothelial cancer.
- TROPION-Breast01Independent statistical analysis of TROPION-Breast01, evaluating Dato-DXd versus investigator's choice of chemotherapy in participants with inoperable or metastatic HR-positive, HER2-negative breast cancer.
- TULIPIndependent statistical analysis of the phase 3 TULIP trial of (vic-)trastuzumab duocarmazine versus physician's choice in participants with HER2-positive locally advanced or metastatic breast cancer, including progression-free survival, overall survival, response, quality…
- VADTIndependent statistical analysis of VADT (NCT00032487), evaluating intensive versus standard glycemic control in type 2 diabetes, with a focus on major macrovascular events, hazard ratios, log-rank testing, confidence intervals, and equivalence testing.
- VELIAIndependent statistical analysis of the VELIA phase 3 trial of veliparib with carboplatin and paclitaxel and as continuation maintenance therapy in adults with newly diagnosed stage III or IV high-grade serous epithelial…
- VESALIUS-CVComplete statistical analysis of VESALIUS-CV, evaluating evolocumab versus placebo in patients at high cardiovascular risk without prior myocardial infarction or stroke. Includes trial design, time-to-event endpoints, hazard ratios, confidence intervals, statistical methodology,…
- VIALE-AIndependent statistical analysis of the phase 3 VIALE-A trial of venetoclax plus azacitidine versus azacitidine in treatment-naive participants with acute myeloid leukemia who are ineligible for standard induction therapy.
- VISIONIndependent statistical analysis of the VISION phase 3 trial of 177Lu-PSMA-617 plus best supportive/best standard of care in metastatic castrate-resistant prostate cancer, including randomized design, time-to-event endpoints, hazard ratios, response analyses, safety,…
- VOYAGER PADA detailed independent statistical analysis of VOYAGER PAD, the randomized phase 3 trial of rivaroxaban plus aspirin versus placebo plus aspirin in symptomatic peripheral artery disease undergoing lower-extremity peripheral revascularization.
- ZUMA-7Independent statistical analysis of ZUMA-7, the randomized phase 3 trial of axicabtagene ciloleucel versus standard of care therapy in relapsed/refractory diffuse large B-cell lymphoma, including event-free survival, response, overall survival, quality of…